Pfizer (PFE) Cash from Discontinued Operations (2010 - 2022)

Pfizer (PFE) has reported Cash from Discontinued Operations for 7 consecutive years, with -$5.0 million the latest figure, recorded in Q3 2022.

• On a quarterly basis, Cash from Discontinued Operations fell 129.41% year-over-year to -$5.0 million in Q3 2022; TTM through Jul 2022 was -$315.0 million, a 109.53% decrease from a year earlier, with the FY2021 full-year figure at -$343.0 million, down 108.88% from the prior year.
• Cash from Discontinued Operations was -$5.0 million for Q3 2022 at Pfizer, up from -$327.0 million in the prior quarter.
• Over five years, Cash from Discontinued Operations peaked at $2.4 billion in Q3 2020 and troughed at -$327.0 million in Q4 2021.
• A 3-year average of $564.4 million and a median of $17.0 million in 2021 frame the typical range for Cash from Discontinued Operations.
• Across the five-year window, Cash from Discontinued Operations plunged 98.07% in 2021 and tumbled 129.41% in 2022, its largest moves.
• Over 3 years, Cash from Discontinued Operations stood at $2.4 billion in 2020, then tumbled by 113.55% to -$327.0 million in 2021, then soared by 98.47% to -$5.0 million in 2022.
• The last three Cash from Discontinued Operations figures came in at -$5.0 million (Q3 2022), -$327.0 million (Q4 2021), and $17.0 million (Q3 2021), per Business Quant data.